All In Biotech

Drug Trial Radar · NCT06422884

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

213

Actual

Start

Nov 15, 2024

Primary completion

Aug 21, 2026

Study completion Aug 21, 2026

Sponsor

Lead sponsor
Endeavor Biomedicines, Inc.Industry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Progressive Fibrosing Interstitial Lung Disease

Interventions

  • ENV-101Drug

    oral tablet, dosed once a day

  • PlaceboDrug

    oral tablet, dosed once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in percent predicted forced vital capacity (ppFVC) compared to placeboTime frame: Baseline and Week 24

Locations

78 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Quilmes, Buenos Aires, Argentina

  • Research Site

    Camperdown, New South Wales, Australia

  • Research Site

    Macquarie Park, New South Wales, Australia

  • Research Site

    Brisbane, Queensland, Australia

  • Research Site

    South Brisbane, Queensland, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Nedlands, Western Australia, Australia

  • Research Site

    Vienna, Austria

  • Research Site

    Graz, Styria, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Dinant, Namur, Belgium

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Ajax, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Trois-Rivières, Quebec, Canada

  • Research Site

    Angers, France

  • Research Site

    Bordeaux, France

  • Research Site

    Caen, France

  • Research Site

    Dijon, France

  • Research Site

    Montpellier, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Paris, France

  • Research Site

    Rennes, France

  • Research Site

    Tours, France

  • Research Site

    Berlin, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Giessen, Hesse, Germany

  • Research Site

    Immenhausen, Hesse, Germany

  • Research Site

    Hanover, Lower Saxony, Germany

  • Research Site

    Essen, North Rhine-Westphalia, Germany

  • Research Site

    Dublin, Ireland

  • Research Site

    Dublin, Leinster, Ireland

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.